Jan 30 (Reuters) - Otsuka Holdings Co Ltd: * OTSUKA HOLDINGS CO LTD: OTSUKA APPLIES FOR ADDITIONAL INDICATION OF ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER FOR REXULTI (BREXPIPRAZOLE) IN JAPAN
Jan 30 (Reuters) - POLYPEPTIDE GROUP AG: * CEO OF POLYPEPTIDE RESIGNS * POLYPEPTIDE GROUP, A FOCUSED GLOBAL CDMO FOR PEPTIDE- AND OLIGONUCLEOTIDE-BASED ACTIVE PHARMACEUTICAL INGREDIENTS, TODAY
* WHO's executive board meets from Jan. 30-Feb. 7 * WHO seeking $6.86 bln for 2024-2025 budget * Body seen pushing for bigger role in global health crises By Jennifer Rigby and Emma Farge GENEVA, Jan
- Source link: (https://bityl.co/Gtyq) - Note: Reuters has not verified this story and does not vouch for its accuracy (Bengaluru newsroom)
Jan 30 (Reuters) - Ryman Healthcare Ltd spokesperson: * SEEN "LIMITED IMPACT TO OUR OPERATIONS" FROM NEW ZEALAND FLOODS Further company coverage:
Jan 30 (Reuters) - Genetic Signatures Ltd: * QUARTERLY SALES OF A$4.7 MILLION; DOWN 12% FROM PRECEDING QUARTER Source text for Eikon: Further company coverage:
Jan 30 (Reuters) - Saintmed PCL: * SIGNED CONTRACT FOR SLEEP TEST SERVICE AT FACULTY OF MEDICINE RAMATHIBODI HOSPITAL * CONTRACT FOR 26.9 MILLION BAHT Source text for Eikon: Further company coverage:
Jan 30 (Reuters) - Rhinomed Ltd: * 1H FY23 UNAUDITED RECOGNISED REVENUE OF A$3.4M Source text for Eikon: Further company coverage:
Jan 30 (Reuters) - Apiam Animal Health Ltd: * ACQUISITION OF TWO MIXED ANIMAL VETERINARY BUSINESSES * DEAL FOR A$11.2 MILLION * CONTINUE ACCELERATED GROWTH PLANS TO INCREASE PRO-FORMA REVENUES TO A
Jan 30 (Reuters) - Somnomed Ltd: * Q2 FY23 REVENUE OF A$21.4 MILLION, UP 16.6% VERSUS PREVIOUS CORRESPONDING PERIOD * SEES FY23 REVENUE GROWTH GUIDANCE HAS BEEN REVISED TO BETWEEN 15-20% * SEES FY23